The federal safety study of mifepristone that could reshape how the abortion pill is dispensed in the United States has not been completed, and the agency's own public status page describes it as still moving through data analysis and peer review.
Two separate developments have moved while that study sits unfinished. The agency approved a third supplier in 2025, joining the brand product and the generic available since 2019. And in late August, the Senate health committee's Republican majority released a report accusing all three sponsors of failing to police the prescribers who sell their product. The rules governing how any of them reach a patient have not changed.
For patients, clinicians, and pharmacists, the practical situation is a mismatch between moving parts. Political and oversight pressure has increased. The rulebook is under review with no published completion date. Anyone trying to plan around either one is working with genuine uncertainty, and it is worth separating what is settled from what is not.
Where the Federal Study Actually Stands
The agency's questions and answers page on mifepristone, last updated in April, describes a study still in progress. As of that update, the agency said it continued working to collect data robust enough to support a well-controlled study with adequate statistical power.
The remaining steps listed are data exploration, evaluation of data integrity, and then implementation of the analyses, validation, and peer review. The agency states that once it finishes its analysis, it will decide whether to make substantive changes to the REMS.
That acronym refers to the Risk Evaluation and Mitigation Strategy, the set of restrictions governing who may prescribe the drug, which pharmacies may dispense it, and what paperwork must accompany it. A modification approved on January 3, 2023, removed the requirement that the drug be handed to a patient in person and added a pharmacy certification requirement in its place.
The agency has offered no firm completion date. It noted that academic studies following the same sequence often take a year or more, and said its plan is to finish sooner than that without cutting corners. Separately, a federal judge in April declined to block mail dispensing nationwide and directed the agency to report back on its review within six months, which sets an outside marker but not a deadline for the study itself.
A Third Supplier Changes Redundancy, Not the Rules
The newest approved generic came from Evita Solutions, which received an abbreviated new drug application approval at the end of September 2025, determining its 200 mg tablets bioequivalent and therapeutically equivalent to the brand product. The company said at the time that the product was expected to be available in January 2026. Independent availability trackers have lagged that timeline, and senators wrote in March 2026 that the company did not appear to have begun marketing the drug, so readers should treat the supply picture as still settling.
A third manufacturer changes redundancy rather than access rules. Every approved product sits inside the same shared safety program, meaning the same prescriber certification, the same patient agreement form, and the same pharmacy certification apply regardless of which manufacturer supplies the tablet.
Andrew Nixon, communications director at the Department of Health and Human Services, framed the approval as a constrained decision, saying the agency has very limited discretion in deciding whether to approve a generic drug. Generic applications are judged on whether the product matches the approved one, not on a fresh review of the underlying medicine.
For households, the near-term effect is mostly financial and logistical. More suppliers can put downward pressure on price and reduce the odds that a single manufacturing problem interrupts supply. Insurance coverage does not update automatically, and plans may add a new generic at the next quarter or plan year rather than immediately. Patients can ask their plan directly whether a specific product is covered and what the out-of-pocket cost would be.
The Adverse Event Record Regulators Are Working From
The safety data the agency currently publishes runs through the end of 2024. Its summary reports 36 deaths associated with mifepristone since approval in September 2000, including two cases of ectopic pregnancy resulting in death and several fatal cases of severe systemic infection.
The agency states these events cannot be attributed to the drug with certainty, citing concurrent use of other drugs, other medical or surgical treatments, coexisting conditions, and gaps in information about patient status and clinical management. It says its review of that information did not identify new safety signals. The full adverse event summary is public.
Those figures are disputed. An analysis published by the Ethics and Public Policy Center, based on an all-payer insurance claims database covering 865,727 prescribed mifepristone abortions from 2017 through 2023, reported a serious adverse event rate of 10.93 percent, far above the figure below 0.5 percent reflected in the approved labeling. That analysis did not undergo external peer review, and clinicians and researchers have challenged its methods, including how it defined a serious adverse event and how it counted emergency department visits. It was a significant driver of political pressure for the current review, and readers should weigh it as a contested claim rather than a settled finding.
Separately, an analysis published in JAMA in January reviewed 264 internal agency documents totaling more than 5,000 pages and covering June 2011 through January 2023. Researchers at Johns Hopkins concluded that agency scientists took a cautious, evidence-driven approach across that period, at times recommending restrictions be retained even after finding the safety profile unchanged.
Congressional Scrutiny and the Open Questions
The Senate Health, Education, Labor, and Pensions Committee opened an investigation in March, sending letters to Danco Laboratories, GenBioPro, and Evita Solutions along with a separate letter to the agency. Chairman Bill Cassidy released the resulting report on August 27. It says the three sponsors could not explain how they ensure that prescribers comply with the safety program, and that none had decertified a prescriber. Companies and congressional Democrats have pointed to the scarcity of reported nonfatal events as evidence of the drug's safety, and the committee's findings reflect the majority's view rather than an agency determination.
Several things remain genuinely unknown. The study has no announced completion date. Whether the agency will modify the safety program is undetermined, and it has committed only to deciding after the analysis is finished. Whether any modification would restore in-person dispensing, adjust prescriber requirements, or leave the program unchanged has not been indicated.
Patients currently prescribed mifepristone should not stop or change a treatment plan because a review is pending, and should direct clinical questions to their prescriber. Anyone weighing options should confirm current requirements with a certified prescriber or pharmacy rather than relying on descriptions of rules that may predate the 2023 modification.
MedicalDaily will report when the agency publishes results of the study or announces a decision on the safety program.
Key Questions Answered
Is the federal safety review finished? No. The agency describes the study as still moving through data exploration, integrity checks, analysis, validation, and peer review. No completion date has been announced.
Have the rules for getting mifepristone changed? No. The safety program modified in January 2023 remains in effect, including certified prescribers, certified pharmacies, and the patient agreement form.
What does a third manufacturer change? Mainly supply redundancy and potential price competition. All approved products operate under the same shared safety program, so dispensing requirements are identical.
How many deaths has the agency recorded? Its summary through the end of 2024 reports 36 deaths since 2000. The agency says these cannot be causally attributed to the drug and that it identified no new safety signals.
Why do some groups cite a much higher complication rate? An analysis from the Ethics and Public Policy Center using insurance claims reported a serious adverse event rate of 10.93 percent. It was not externally peer-reviewed, and its methods have been disputed.
What did the Senate committee report find? The Republican majority concluded that the three approved sponsors could not show how they verify prescriber compliance with the safety program and had never decertified a prescriber.
Should a patient change anything right now? No. An ongoing review is not a safety finding. Patients with questions should speak with a certified prescriber rather than acting on the fact that a review is pending.
